Utilisation of Non-steroidal Anti-inflammatory Drugs (NSAIDs) through Community Pharmacies in Malaysia

Abstract

This study was conducted to evaluate the use of non-steroidal anti-inflammatory drugs (NSAIDs) by consumers who obtained these drugs from community pharmacies. Factors that influenced community pharmacists in their choice of NSAIDs were also determined. Personal interviews were conducted on consumers who visited the 25 participating community pharmacies throughout Malaysia. Of the 389 respondents, 49% requested for an NSAID by name, 42% asked the pharmacist to recommend a medication and 9% had a doctor's prescription. NSAIDs were mainly purchased for joint/shoulder pain and the most commonly dispensed was diclofenac. Elderly respondents were more likely to be dispensed a selective COX-2 inhibitor than those below 60. NSAIDs were recommended based mainly on the pharmacist's perception of their efficacy, cost and safety. Community pharmacists play an important role in assisting patients in choosing the most appropriate NSAID for their health problems. Asia Pac J Public Health 2005; 17(2): 117-123.

Keywords

Community pharmacy gastrointestinal NSAID nonsteroidal anti-inflammatory selective COX-2 inhibitors side effect.

Get full access to this article

View all access options for this article.

References

American Society of Health-System Pharmacists. ASHP Therapeutic Position Statement on the Safe Use of Oral Nonprescription Analgesics. Am J Health-Sy Pharm 1999; 56(11): 1126-1131.

Griffin MR Epidemiology of NSAID associated gastrointestinal injury. Am J Med 1998; 104(3A): 23S 29S.

Brooks PM Use and benefits of non steroidal anti inflammatory drugs. Am J Med 1998; 104(3A): 9S 13S.

Hawkey CJ , Cullen Dje , Pearson G. et al. Pharmacoepidemiology of NSAIDs use in Nottingham general practices . Aliment Pharmacol Ther 2000; 14: 177-185.

McManus P. , Primrose JG , Henry DA et al. Pattern of non steroidal anti-inflammatory drugs use in Australia 1990-1994. Med J Aust 1996; 164: 589-592.

Brooks PM , Day RO Nonsteroidal anti-inflammatory drugs - differences and similarities. New Engl J Med 1991; 324(24): 1716-1725.

Furst DE

Are there differences among nonsteroidal anti-inflammatory drugs?

Arthritis Rheum 1994; 37(1):1 9.

Gabriel SE , Jaakkimainen L. , Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115: 87-796.

Greene JM , Winickoff RN Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions. Arch Intern Med 1992;152: 1995-2001.

10.

Day R. COX-2 Specific Inhibitors: Safer Anti-inflammatory Therapy? Med Progress 2000; 27(11):17 — 22.

11.

Benrimoj SI , Chua SS Predictors of non-prescription medication use. J Pharm Mark Manage 1990; 5(1): 3-27.

12.

McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998; 195(5A): 3S-9S.

13.

FitzGerald GA Coxibs and cardiovascular disease. New Engl J Med 2004; 351(17): 1709-11.

14.

Anon. Vioxx: an unequal partnership between safety and efficacy . Lancet 2004; 364(9442): 1287-88.

15.

Cutts C. , LaCaze A. , Tett S. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. Br J Clin Pharmacol 2002; 54: 522-527.

16.

Whelton A. Renal and Related Cardiovascular Effects of Conventionai and COX-2 Specific NSAID and Non-NSAID Analgesics. Am J Ther 2000; 7(2): 63-74.

17.

Beilin LJ Non-steroidal anti-inflammatory drugs and antihypertensive drug therapy. J Hyperten 2002; 20: 849-850.

18.

Sift R. , Tjeerd-Pieter VS , LucienA and Ebner D. A Study of the utilization of Non-Steroidal Anti-Inflammatory Drugs Using a Pharmacy-based Approach. Pharmacoepidemiol Drug Saf 1995; 4: 225-230.

19.

Henry D. , Lim Lly , Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual NSAIDs: results of a collaborative meta analysis. BMJ 1996; 321: 1563-1566.

20.

Goldstein JL , Kivitiz AJ , Verburg KM , Recker DP , Palmer RC , Kent JD A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects . Aliment Pharmacol Ther 2003; 18(1): 125-132.

21.

Hawkey CJ , Laine L. , Simon T. , Quan H. , Shingo S. , Evans J. Rofecoxib Rheumatoid Arthritis Endoscopy Study Group. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003; 52(6): 820-826.

22.

Mamdani M. , Rochon PA , Juurlink DN , et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002a; 325: 1-6.

23.

McMurray RW , Hardy KJ Cox-2 inhibitors: today and tomorrow. Am J Med Sci 2002; 323(4):181-189.

24.

Crawford AS , White JG Celecoxib-induced upper gastrointestinal hemorrhage and ulceration. South Med J 2002; 95(12): 1444-6.

25.

Foral PA , Wilson AF , Nystrom KK Gastrointestinal bleeds associated with rofecoxib. Pharmacotherapy 2002; 22(3): 384-386.

26.

Marshall JK , Pellissier JM , Attard CL , Kong SX , Marentette MA Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis. Ontario Ministry of Health perspective. Pharmacoeconomics 2001 ; 19(10): 1039-1049.

27.

You Jhs , Lee Kkc , Chan Tyk , Lau WH , Chan Fkl. Arthritis treatment in Hong Kong — cost analysis of celecoxib versus conventional NSAIDs, with or without gastroprotective agents. Aliment Pharmacol Ther 2002;16: 2089-2096.

28.

Mamdani M. , Rochon P. , Laupacis A. , Anderson G. Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. Can Med Assoc J 2002b; 167(10):1125-1126.